• 1. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 4. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 5. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849

• Solvents and Organic Chemicals Organic Compounds Organometallic compounds Organometalloid compounds Organosilicon compounds Siloxanes
• Other Chemical Reagents Organic Metal Reagents

Research Briefing on 2,2,4,4-Tetramethyl-3,8,11,14-tetraoxa-2,4-disilapentadecane (CAS: 17065-99-5)

The compound 2,2,4,4-Tetramethyl-3,8,11,14-tetraoxa-2,4-disilapentadecane (CAS: 17065-99-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This siloxane-based molecule, characterized by its unique structural properties, has been explored for its potential applications in drug delivery systems, biomaterial coatings, and as a stabilizing agent in various formulations. Recent studies have focused on its physicochemical properties, biocompatibility, and interactions with biological systems, making it a promising candidate for advanced therapeutic and diagnostic applications.

One of the key areas of research involving 2,2,4,4-Tetramethyl-3,8,11,14-tetraoxa-2,4-disilapentadecane is its role in enhancing the stability and bioavailability of hydrophobic drugs. A 2023 study published in the *Journal of Controlled Release* demonstrated that this compound can form stable micellar structures when combined with certain amphiphilic polymers, thereby improving the solubility and sustained release of poorly water-soluble drugs. The study highlighted the compound's ability to reduce drug aggregation and enhance cellular uptake, which is critical for improving therapeutic outcomes in cancer and other diseases.

Another notable application of this compound is in the development of biocompatible coatings for medical devices. Research conducted by a team at MIT and published in *Biomaterials Science* in early 2024 revealed that 2,2,4,4-Tetramethyl-3,8,11,14-tetraoxa-2,4-disilapentadecane can be used to create thin, durable films on implant surfaces, significantly reducing bacterial adhesion and biofilm formation. This property is particularly valuable for preventing infections associated with catheters, stents, and other indwelling medical devices. The study also noted the compound's low cytotoxicity and excellent hemocompatibility, further supporting its suitability for clinical use.

In addition to its biomedical applications, recent investigations have explored the compound's potential in nanotechnology. A 2024 paper in *ACS Nano* reported that 2,2,4,4-Tetramethyl-3,8,11,14-tetraoxa-2,4-disilapentadecane can serve as a versatile linker for the surface functionalization of nanoparticles. By leveraging its siloxane backbone, researchers were able to attach targeting ligands and therapeutic payloads to gold and silica nanoparticles, enabling precise drug delivery and imaging. The study underscored the compound's role in advancing theranostic platforms, which combine therapy and diagnostics into a single system.

Despite these promising findings, challenges remain in the widespread adoption of 2,2,4,4-Tetramethyl-3,8,11,14-tetraoxa-2,4-disilapentadecane. For instance, its long-term stability under physiological conditions and potential immunogenicity require further investigation. Ongoing studies are focusing on optimizing its synthesis and derivatization to enhance its performance and safety profile. Collaborative efforts between academia and industry are expected to accelerate the translation of these discoveries into practical applications.

In conclusion, 2,2,4,4-Tetramethyl-3,8,11,14-tetraoxa-2,4-disilapentadecane (CAS: 17065-99-5) represents a versatile and innovative tool in chemical biology and pharmaceutical research. Its unique properties and multifunctional applications make it a valuable asset for drug delivery, medical device coatings, and nanotechnology. As research progresses, this compound is poised to play a pivotal role in addressing some of the most pressing challenges in modern medicine.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)